The FDA published a document yesterday around the detection of small molecule nitrosamines, specifically NDBA being detected in infusion bags, potentially from printed overwraps and packaging.
Would be useful to know if NDBA leaching from IV bag is demonstrated also when no IV bag ports (cf. possible rubber seal NDBA risk, linked with zinc dibutyldithiocarbamate) are used to sample the liquid for testing (and which IV bag types have shown a risk, as there are many polymer types).
But I guess indeed inkjet printing is sufficiently common for IV bags, and dibutylamine use in inkjet inks as well to support the plausibility of the root cause (probably liquid sampled from unprinted bags have been tested as well to shown absence).
Similar to the new guidelines for ICH Q3E on extractables and leachables, where there is a requirement to consider the impact of labels applied to semi-permeable bottles etc. - the whole package needs to be thought of as a potential source of impurities within the product, sometimes when not even in direct contact.
I think that you have pointed out something that FDA’s information misses. A significant source of NDBA is butylated rubber seal. While ink could be a significant source too, but leachable NDBA from rubber stoppers have been known forever and I think the rubber seal is more in contact with large volume parenteral than the ink.
I agree compounds like dibutylamine and Dibenzylamine have been reported in literature as an extractable from polyisoprene stopper and both are precursor of Nitrosamine impirities N Nitroso Dibenzylamine and N Nitroso dibutylamine